For Media: UK Press Releases

Bayer receives MHRA authorisation for new indication of Nubeqa® (darolutamide) plus androgen deprivation therapy as a treatment option in metastatic hormone-sensitive prostate cancer

Data from Phase III OASIS-4 study to be presented at 2025 ASCO Annual Meeting

Bayer receives MHRA authorisation for...

Bayer’s investigational MRI contrast agent gadoquatrane meets primary and main secondary endpoints in Phase III studies

Elinzanetant meets all primary and secondary endpoints in Phase III study OASIS 4 for treatment of moderate to severe vasomotor symptoms caused by breast cancer treatments

Bayer receives positive CHMP opinion for acoramidis for treatment of adults with transthyretin amyloid cardiomyopathy with UK MHRA submission underway

Five crop science projects funded under Bayer – Niab Challenge Grant Program